Center for Global Health Research(CGHR-Kisumu)

Center for Global Health Research(CGHR-Kisumu)


The Centre for Global Health Research (CGHR) is located in Kisumu, Western Kenya. The facility was originally inherited from the former East African Medical Research Council.

In 1984, the station was named Malaria and Other Protozoal Diseases Centre (MOPDC) later changing to Vector Biology and Control Research Centre (VBCRC),  then Centre for Vector Biology and Control Research (CVBCR) and finally Center for Global Health Research (CGHR).  The Centre is today one of the 15 Research Centres of the Kenya Medical Research Institute (KEMRI). The Centre is strategically located in Kisumu City, western Kenya region, in an area that is endemic for major infectious diseases.

Since its establishment in 1984, CGHR has been on the world map as the site of ground-breaking research focusing on infectious diseases of medical importance. Specifically, the Centre has carried out cutting-edge research focusing on trials on the efficacy of drugs, emergence of drug and vector resistance, epidemiology, immunology, molecular biology, vector biology, climate and human health, characterization of malaria vaccine candidate antigens, malaria vaccine trials, malaria in pregnancy and interaction of malaria and human immunodeficiency virus (HIV), schistosomiasis, intestinal helminthes, HIV/AIDS and its impact on the community, HIV interaction with other infectious diseases, tuberculosis and reproductive health.


Our mission is to improve human health and quality of life through research, capacity building, innovation and service delivery


Our vision is to be a leading centre of excellence in research for human health


  1. To conduct evidence based research aimed at providing solutions for the reduction of infectious, parasitic, non-infectious diseases and other causes of ill-health in Kenya.

This includes, but not limited to:

  • Epidemiology and control of Infectious, Non-Communicable and Lifestyle Diseases.
  • Molecular Biology, Immunology, Pathophysiology and Genetics of diseases of public health importance
  • Vectors of diseases; their biology and ecology, development and evaluation of control tools and IR
  • Clinical trials and monitoring drug resistance. 
  • Climate change and human health.
  • Behavioural/Social Science Research in Public Health
  • Emerging and Reemerging Diseases
  1. Provide training and capacity building in public health
  2. Provide leadership in human health research
  3. Promote and sustain excellence in research
  4. Strengthen principles of good corporate governance
  5. Disseminate and translate research findings for evidence based policy formulation and implementation
  6. Strengthen research partnerships and relationships with stakeholders


  • A demographic surveillance system (DSS) in the previous bed net study area aimed at establishing a high quality surveillance system in a population of 135,000 and provide an infrastructure that will yield reliable demographic
    data and serve as a platform to evaluate the impact of public health interventions on morbidity and mortality.
  • Population genetics of malaria vectors.
  • The effects of climate change on human health.
  • The epidemiology and immunology of malaria epidemics in the highlands.
  • Immunology of malaria during pregnancy.
  • The genetic basis of severe malarial anemia in young children.
  • A study to assess the impact of co-trimoxazole prophylaxis on development of anti-folate resistance in pathogens of public health importance including P. falciparum, S. pneumoniae, and enteric bacteria.
  • A study on the In-vivo response of P. falciparum to antimalarial treatment in HIV-infected and HIV-uninfected individuals.


  • A community-based trial on the impact of insecticide-treated bed nets on childhood morbidity and mortality in an area of intense and perennial malaria transmission in western Kenya,
  • The interaction of malaria and HIV in pregnant women and the immuno-epidemiology of malaria in western Kenya,
  • The Asembo Bay Cohort Project.

The Neglected Tropical Diseases (NTD) Unit hosted at CGHR brings together different researchers working on disease specific aspects of NTDs at KEMRI. The Unit addresses the critical need to align research program with national and current global agenda.


Neglected Tropical Diseases

Malaria remains an important public health problem and an impediment to social and economic development in sub-Saharan Africa. In Kenya malaria is one of the leading causes of morbidity and mortality and 80 percent of the population is at risk.


Malaria Branch

Entomology Division

The Neglected Tropical Diseases (NTD) Unit hosted at CGHR brings together different researchers working on disease specific aspects of NTDs at KEMRI. The Unit addresses the critical need to align research program with national and current global agenda.



Health Demographic Surveillance Systems Division

HIV Implementation Science and Services (HISS)

One Health Research Division

Non-Communicable Diseases Division

Global Health and Protection Division

Climate and Human Health Research Division

Support Services

Clinical Services support

Evidence on best Deworming strategies to be employed for Mass Drug Administration (MDA) against Helminth infections:

Preventive chemotherapy is considered the key component in the control of Schistosomiasis and intestinal worms, and among questions that have been addressed on our research platform is how different deworming strategies (whether community-wide or school-based) impact on morbidity in areas with different infection prevalence thresholds. Some of the data from our Schistosomiasis Consortium for Operational Research (SCORE) studies is currently being shared with the Ministry of Health in order to provide evidence on the best combination of deworming strategies based on prevalence thresholds, both in terms of duration and frequency of MDAs.

Evidence of Schistosomiasis in pre-school age children (< 5 years) and need for change in deworming policy: The WHO recommended control strategy of Schistosomiasis is based on preventive chemotherapy interventions targeting the majority of the at-risk population. The current gold standard treatment employs annual single oral dose of the drug Praziquantel (PZQ) 600 mg tablets for adults and school age children at 40 mg/kg. However, pre-School Aged Children (pre-SAC), which are a high-risk group for Schistosome infections accounting for 10-20 million of the global prevalence, are currently not included during treatment campaigns due to the lack of a suitable PZQ pediatric formulation. In this regard, a pediatric schistosomiasis consortium was formed in July 2012 under the leadership of Merck with the goal of developing a suitable pediatric formulation of PZQ for pre-SAC and register its use in schistosomiasis.

Evidence for schistosomiasis transmission in urban setting: Schistosomiasis has always been considered a rural phenomenon. However, our research in an informal urban setting has provided evidence not only for the occurrence of schistosomiasis in an urban setting, but also active transmission in situ. These findings have informed the inclusion of such otherwise neglected settings in National deworming programs, and the strategies to use in such settings.

Deworming activities targeting Schistosomiasis and Soil-transmitted Helminths:

Over the last 5 years, and in partnership with the Ministry of Health, over 70,000 individuals in most at risk areas were dewormed annually in our annual Mass Drug Administration programs targeting Schistosomiasis and Soil-Transmitted Helminths (STH), conducted by three key NTD projects in western Kenya. Health education and awareness campaigns were also embedded in the deworming activities, and are a continuous activity.

Annual NTD Conference:

We have over the years successfully hosted the annual Neglected Tropical Diseases (NTD) Conference. In 2016, the 10th annual NTD Conference was jointly hosted by the KEMRI’s NTD Unit and the Ministry of Health’s NTD Unit. This annual event presents an important and unique forum for showcasing and disseminating research findings from our studies to other stakeholders and partners from the Ministry of Health, local universities and other Non-governmental agencies working on NTDs.



Dr. Stephen Munga is a highly experienced, researcher, technical advisor and public health manager. He has been a technical advisor to World Health Organization in Kenya, Botswana, Namibia and Uganda Malaria Program Reviews (MPRs).

He has conducted desk review of Malaria Epidemic Preparedness and Response/Indoor Residual Spray program and Vector Control components of the National Malaria Control Programs and wrote two  manuscripts from the Kenya Malaria Review Program Final Report.

Dr. Munga is part of the team that reviewed guidelines used for Malaria Program Reviews used for Epidemic Preparedness and Response (EPR) other guidelines by WHO Inter-Country Support Team (WHO-IST, Harare) in Victoria Falls.

Dr. Munga, participated in writing the National Malaria Strategy (2009 – 2017), Integrated Vector Management (IVM) Policy for Kenya and Technical Guidelines for Epidemic Preparedness and Response for Kenya.

He has been a technical advisor, for a Health System Strengthening Program in North Eastern Province, Kenya for two years and wrote Annual Reports to the funding organization (COMIC Relief), a, technical advisor to program on evaluation ZeroVector (durable wall lining) and Indoor Residual Spray in Liberia

Besides, has been a co-principal investigator and a manager in several projects in western Kenya and North Eastern regions providing technical support, logistic, administrative and financial support in areas of health system strengthening, insecticide resistance, evaluation of durable wall linings, and targeted malaria vector control climate variability and change and diseases.

In addition, Dr. Munga is a Post-Doctoral Fellow at the International Centre for Insect Physiology and Ecology (ICIPE) providing technical advice, monitoring and evaluation and support to technical staff including ensuring that their objectives are set, work plans developed and implemented, and their performance is regularly reviewed. In 2007, Dr. Munga worked with permission from his employer, as a Senior Guest Researcher at the Nile Basin Research Program, University of Bergen, Norway dealing with Climate Change and Human Health.

Dr. Stephen Munga

Contact Us

Kenya Medical Research Institute

Centre for global health research

P.O Box 20778-00202 Kisumu Tel: +254 020 2726781

+254 020 2722541, +254 020 2713349, 0722205901


Email: cghr@kemri.org

Your Name (required)

Your Email (required)


Your Message

KEMRI AT 40 40 (1)